Trade Report: The Alexion Pharmaceuticals Inc. (ALXN) Announces Quarterly Earnings Results, Beats Estimates By $0.19 EPS

The Alexion Pharmaceuticals Inc. (ALXN) Announces Quarterly  Earnings Results, Beats Estimates By $0.19 EPS

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) released its quarterly earnings results on Thursday. The biopharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.04 by $0.19. The firm had revenue of $799 million for the quarter, compared to analysts’ expectations of $787.07 million. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The business’s quarterly revenue was up 19.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.16 earnings per share.

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 135.59 on Monday. The firm’s 50 day moving average is $125.04 and its 200-day moving average is $132.89. The company has a market cap of $30.40 billion, a P/E ratio of 82.68 and a beta of 1.33. Alexion Pharmaceuticals has a 52 week low of $110.56 and a 52 week high of $193.45.

Several research firms have recently weighed in on ALXN. Credit Suisse Group AG raised shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a report on Saturday, July 9th. Royal Bank Of Canada began coverage on Alexion Pharmaceuticals in a research note on Tuesday, July 12th. They issued an “outperform” rating and a $188.00 target price on the stock. Wedbush increased their target price on Alexion Pharmaceuticals from $132.00 to $135.00 and gave the company a “neutral” rating in a research note on Friday. Leerink Swann increased their target price on Alexion Pharmaceuticals from $210.00 to $211.00 and gave the company an “outperform” rating in a research note on Monday, September 26th. Finally, Cowen and Company reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Thursday, September 22nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $175.23.

In other Alexion Pharmaceuticals news, CEO David Hallal sold 332 shares of the company’s stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $137.14, for a total value of $45,530.48. Following the transaction, the chief executive officer now directly owns 189,266 shares in the company, valued at approximately $25,955,939.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Carsten Thiel sold 4,584 shares of the company’s stock in a transaction dated Friday, October 14th. The stock was sold at an average price of $120.28, for a total transaction of $551,363.52. Following the completion of the transaction, the executive vice president now owns 32,741 shares in the company, valued at $3,938,087.48. The disclosure for this sale can be found here. Corporate insiders own 4.41% of the company’s stock.

Institutional investors have recently modified their holdings of the company. FMR LLC increased its position in shares of Alexion Pharmaceuticals by 12.0% in the second quarter. FMR LLC now owns 18,745,795 shares of the biopharmaceutical company’s stock worth $2,188,759,000 after buying an additional 2,002,085 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Alexion Pharmaceuticals by 1.6% in the second quarter. Vanguard Group Inc. now owns 13,478,718 shares of the biopharmaceutical company’s stock worth $1,573,774,000 after buying an additional 216,269 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Alexion Pharmaceuticals by 13.7% in the second quarter. Ameriprise Financial Inc. now owns 6,025,775 shares of the biopharmaceutical company’s stock worth $703,575,000 after buying an additional 728,182 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in shares of Alexion Pharmaceuticals by 1.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 5,686,354 shares of the biopharmaceutical company’s stock worth $663,939,000 after buying an additional 84,485 shares in the last quarter. Finally, BlackRock Fund Advisors increased its position in shares of Alexion Pharmaceuticals by 3.1% in the second quarter. BlackRock Fund Advisors now owns 4,564,948 shares of the biopharmaceutical company’s stock worth $533,003,000 after buying an additional 135,363 shares in the last quarter. Institutional investors and hedge funds own 96.36% of the company’s stock.

About Alexion Pharmaceuticals

Related posts

Leave a Comment